An essential introduction to the 2023 guideline for diagnosis and treatment patients with hypertrophic cardiomyopathy
-
摘要: 本文主要介绍《中国成人肥厚型心肌病诊断与治疗指南2023》的基本内容和更新要点，有助于规范肥厚型心肌病的临床诊治并有效改善患者预后，供临床同行参考。Abstract: This article introduces the basic contents and renewal points of the latest published 2023 Guidelines for Diagnosis and Treatment for Chinese Adult Patients with Hypertrophic Cardiomyopathy(HCM), which standardize the clinical diagnosis and management of HCM to improve prognosis of patients.
-
Key words:
- hypertrophic cardiomyopathy /
- adult /
- guide interpretation
-
-
图 1 HCM的SCD危险评价和干预策略
Figure 1. Risk assessment and intervention strategies for SCD in HCM
-
[1] 国家心血管病中心心肌病专科联盟, 中国医疗保健国际交流促进会心血管病精准医学分会"中国成人肥厚型心肌病诊断与治疗指南2023"专家组. 中国成人肥厚型心肌病诊断与治疗指南2023[J]. 中国循环杂志, 2023, 38(1): 1-33. https://www.cnki.com.cn/Article/CJFDTOTAL-SYXL202303028.htm
[2] Hershberger RE, Givertz MM, Ho CY, et al. Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics(ACMG)[J]. Genet Med, 2018, 20(9): 899-909. doi: 10.1038/s41436-018-0039-z
[3] Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology(ESC)[J]. Eur Heart J. 2014, 35(39): 2733-2779. doi: 10.1093/eurheartj/ehu284
[4] Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. J Am Coll Cardiol, 2020, 76(25): e159-e240. doi: 10.1016/j.jacc.2020.08.045
[5] Maron BJ, Desai MY, Nishimura RA, et al. Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review[J]. J Am Coll Cardiol, 2022, 79(4): 390-414. doi: 10.1016/j.jacc.2021.11.021
[6] Liu J, Wu G, Zhang C, et al. Improvement in sudden cardiac death risk prediction by the enhanced American College of Cardiology/American Heart Association strategy in Chinese patients with hypertrophic cardiomyopathy[J]. Heart Rhythm, 2020, 17(10): 1658-1663. doi: 10.1016/j.hrthm.2020.04.017
[7] Green EM, Wakimoto H, Anderson RL, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice[J]. Science, 2016, 351(6273): 617-621. doi: 10.1126/science.aad3456
[8] Chuang C, Collibee S, Ashcraft L, et al. Discovery of Aficamten(CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy[J]. J Med Chem, 2021, 64(19): 14142-14152.
[9] Liu L, Liu B, Li J, et al. Percutaneous intramyocardial septal radiofrequency ablation of hypertrophic obstructive cardiomyopathy: a novel minimally invasive treatment for reduction of outflow tract obstruction[J]. Euro Int, 2018, 13(18): e2112-e2113.
[10] Cooper RM, Shahzad A, Hasleton J, et al. Radiofrequency ablation of the interventricular septum to treat outflow tract gradients in hypertrophic obstructive cardiomyopathy: a novel use of CARTOSound® technology to guide ablation[J]. Europace, 2016, 18(1): 113-120. http://europace.oxfordjournals.org/content/18/1/113
-
下载:
图(2)
计量
- 文章访问数: 1292
- PDF下载数: 319
- 施引文献: 0